Allogene to present Phase 1 Data from ALLO-501/501A trials at ASCO

Allogene Therapeutics announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the American Society of Clinical Oncology, or ASCO, Annual Meeting June 2-6. The ALPHA/ALPHA2 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19. In addition to exploring cell doses, these studies evaluated escalating doses of ALLO-647, Allogene’s proprietary lymphodepleting antibody designed to prevent premature rejection of AlloCAR T cells. Allogene is currently enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in large B cell lymphoma, or LBCL. "We are looking forward to sharing updated data from our Phase 1 ALPHA/ALPHA2 trials. Prior updates from the ALPHA/ALPHA2 trials provided clear proof-of-concept for the ability of an allogenic CAR T product candidate to induce deep and durable responses in LBCL, a crucial finding as we seek to establish a new era in CAR T," said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research & Development and Chief Medical Officer.